UKT-04 trial of continuous metronomic low-dose chemotherapy with methotrexate and cyclophosphamide for recurrent glioblastoma
Glioblastoma is a highly angiogenic tumor with a dismal prognosis. Continuous oral low-dose chemotherapy with methotrexate (MTX) and cyclophosphamide (CPM) has modest activity in heavily pretreated patients with breast cancer. We explored the efficacy of 100 mg CPM daily and 5 mg MTX twice weekly in...
Gespeichert in:
| Veröffentlicht in: | Journal of neuro-oncology 2005-02, Vol.71 (3), p.295-299 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 299 |
|---|---|
| container_issue | 3 |
| container_start_page | 295 |
| container_title | Journal of neuro-oncology |
| container_volume | 71 |
| creator | HERRLINGER, Ulrich RIEGER, Johannes STEINBACH, Joachim P NÄGELE, Thomas DICHGANS, Johannes WELLER, Michael |
| description | Glioblastoma is a highly angiogenic tumor with a dismal prognosis. Continuous oral low-dose chemotherapy with methotrexate (MTX) and cyclophosphamide (CPM) has modest activity in heavily pretreated patients with breast cancer. We explored the efficacy of 100 mg CPM daily and 5 mg MTX twice weekly in relapsed glioblastoma. Ten patients, 22-59 years old, with a Karnofsky score of 50% or higher who had failed at least two chemotherapies were accrued. No toxicity was observed. No patient showed a complete or partial response. Five of 10 patients progressed within 2 months of therapy. Another five patients progressed after 3-4.5 months. The median time to progression was 2.5 months. The median overall survival after start of MTX/CPM was 6.9 months (range 0.5-18.8 months). Since the progression-free survival rate at 6 months was 0%, the trial was prematurely closed. |
| doi_str_mv | 10.1007/s11060-004-1726-y |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_20634101</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>20634101</sourcerecordid><originalsourceid>FETCH-LOGICAL-c387t-628e9d153236954a159895891f26db7c604a9d6e7fe1e54ff8243b50adaf6bdd3</originalsourceid><addsrcrecordid>eNpd0ctq3TAQBmBRGprTtA_QTRGFdqdUsizJWpaQXkigmwS6E7I0qh1sy5VkEi_67rU5BwJdzeab0Yx-hN4xeskoVZ8zY1RSQmlNmKokWV-gAxOKE8UVf4kOlElFhK5_naPXOT_QDSrOXqHzHQld0QP6e39zR2iNS-rtgGPALk6ln5a4ZDxCSXGKY-_wEB-Jjxmw62CMpYNk5xU_9qXbVRdLgidbANvJY7e6Ic5dzHNnx94DDjHhBG5JCaaCfw99bAebSxztG3QW7JDh7aleoPuv13dX38ntz28_rr7cEscbVYisGtCeCV5xqUVtmdCNFo1moZK-VU7S2movQQVgIOoQmqrmraDW2yBb7_kF-nScO6f4Z4FczNhnB8NgJ9guNRWVvGaUbfDDf_AhLmnadjMV25_Umm-IHZFLMecEwcypH21aDaNmD8YcgzHbf5s9GLNuPe9Pg5d2BP_ccUpiAx9PwGZnh5Ds5Pr87KTk1bYA_wd7BJhw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>219589993</pqid></control><display><type>article</type><title>UKT-04 trial of continuous metronomic low-dose chemotherapy with methotrexate and cyclophosphamide for recurrent glioblastoma</title><source>MEDLINE</source><source>SpringerLink Journals - AutoHoldings</source><creator>HERRLINGER, Ulrich ; RIEGER, Johannes ; STEINBACH, Joachim P ; NÄGELE, Thomas ; DICHGANS, Johannes ; WELLER, Michael</creator><creatorcontrib>HERRLINGER, Ulrich ; RIEGER, Johannes ; STEINBACH, Joachim P ; NÄGELE, Thomas ; DICHGANS, Johannes ; WELLER, Michael</creatorcontrib><description>Glioblastoma is a highly angiogenic tumor with a dismal prognosis. Continuous oral low-dose chemotherapy with methotrexate (MTX) and cyclophosphamide (CPM) has modest activity in heavily pretreated patients with breast cancer. We explored the efficacy of 100 mg CPM daily and 5 mg MTX twice weekly in relapsed glioblastoma. Ten patients, 22-59 years old, with a Karnofsky score of 50% or higher who had failed at least two chemotherapies were accrued. No toxicity was observed. No patient showed a complete or partial response. Five of 10 patients progressed within 2 months of therapy. Another five patients progressed after 3-4.5 months. The median time to progression was 2.5 months. The median overall survival after start of MTX/CPM was 6.9 months (range 0.5-18.8 months). Since the progression-free survival rate at 6 months was 0%, the trial was prematurely closed.</description><identifier>ISSN: 0167-594X</identifier><identifier>EISSN: 1573-7373</identifier><identifier>DOI: 10.1007/s11060-004-1726-y</identifier><identifier>PMID: 15735920</identifier><identifier>CODEN: JNODD2</identifier><language>eng</language><publisher>Dordrecht: Springer</publisher><subject>Adult ; Angiogenesis Inhibitors - administration & dosage ; Angiogenesis Inhibitors - therapeutic use ; Antineoplastic Combined Chemotherapy Protocols - therapeutic use ; Biological and medical sciences ; Brain Neoplasms - drug therapy ; Brain Neoplasms - mortality ; Brain Neoplasms - secondary ; Breast Neoplasms - drug therapy ; Breast Neoplasms - mortality ; Breast Neoplasms - pathology ; Cyclophosphamide - administration & dosage ; Disease-Free Survival ; Dose-Response Relationship, Drug ; Drug Administration Schedule ; Drug Resistance, Neoplasm ; Female ; Glioblastoma - drug therapy ; Glioblastoma - mortality ; Glioblastoma - secondary ; Hormones. Endocrine system ; Humans ; Male ; Medical sciences ; Methotrexate - administration & dosage ; Middle Aged ; Neoplasm Recurrence, Local - drug therapy ; Neoplasm Recurrence, Local - mortality ; Neurology ; Pharmacology. Drug treatments ; Tumors of the nervous system. Phacomatoses</subject><ispartof>Journal of neuro-oncology, 2005-02, Vol.71 (3), p.295-299</ispartof><rights>2005 INIST-CNRS</rights><rights>Springer 2005</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c387t-628e9d153236954a159895891f26db7c604a9d6e7fe1e54ff8243b50adaf6bdd3</citedby><cites>FETCH-LOGICAL-c387t-628e9d153236954a159895891f26db7c604a9d6e7fe1e54ff8243b50adaf6bdd3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=16632958$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/15735920$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>HERRLINGER, Ulrich</creatorcontrib><creatorcontrib>RIEGER, Johannes</creatorcontrib><creatorcontrib>STEINBACH, Joachim P</creatorcontrib><creatorcontrib>NÄGELE, Thomas</creatorcontrib><creatorcontrib>DICHGANS, Johannes</creatorcontrib><creatorcontrib>WELLER, Michael</creatorcontrib><title>UKT-04 trial of continuous metronomic low-dose chemotherapy with methotrexate and cyclophosphamide for recurrent glioblastoma</title><title>Journal of neuro-oncology</title><addtitle>J Neurooncol</addtitle><description>Glioblastoma is a highly angiogenic tumor with a dismal prognosis. Continuous oral low-dose chemotherapy with methotrexate (MTX) and cyclophosphamide (CPM) has modest activity in heavily pretreated patients with breast cancer. We explored the efficacy of 100 mg CPM daily and 5 mg MTX twice weekly in relapsed glioblastoma. Ten patients, 22-59 years old, with a Karnofsky score of 50% or higher who had failed at least two chemotherapies were accrued. No toxicity was observed. No patient showed a complete or partial response. Five of 10 patients progressed within 2 months of therapy. Another five patients progressed after 3-4.5 months. The median time to progression was 2.5 months. The median overall survival after start of MTX/CPM was 6.9 months (range 0.5-18.8 months). Since the progression-free survival rate at 6 months was 0%, the trial was prematurely closed.</description><subject>Adult</subject><subject>Angiogenesis Inhibitors - administration & dosage</subject><subject>Angiogenesis Inhibitors - therapeutic use</subject><subject>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</subject><subject>Biological and medical sciences</subject><subject>Brain Neoplasms - drug therapy</subject><subject>Brain Neoplasms - mortality</subject><subject>Brain Neoplasms - secondary</subject><subject>Breast Neoplasms - drug therapy</subject><subject>Breast Neoplasms - mortality</subject><subject>Breast Neoplasms - pathology</subject><subject>Cyclophosphamide - administration & dosage</subject><subject>Disease-Free Survival</subject><subject>Dose-Response Relationship, Drug</subject><subject>Drug Administration Schedule</subject><subject>Drug Resistance, Neoplasm</subject><subject>Female</subject><subject>Glioblastoma - drug therapy</subject><subject>Glioblastoma - mortality</subject><subject>Glioblastoma - secondary</subject><subject>Hormones. Endocrine system</subject><subject>Humans</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Methotrexate - administration & dosage</subject><subject>Middle Aged</subject><subject>Neoplasm Recurrence, Local - drug therapy</subject><subject>Neoplasm Recurrence, Local - mortality</subject><subject>Neurology</subject><subject>Pharmacology. Drug treatments</subject><subject>Tumors of the nervous system. Phacomatoses</subject><issn>0167-594X</issn><issn>1573-7373</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2005</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><recordid>eNpd0ctq3TAQBmBRGprTtA_QTRGFdqdUsizJWpaQXkigmwS6E7I0qh1sy5VkEi_67rU5BwJdzeab0Yx-hN4xeskoVZ8zY1RSQmlNmKokWV-gAxOKE8UVf4kOlElFhK5_naPXOT_QDSrOXqHzHQld0QP6e39zR2iNS-rtgGPALk6ln5a4ZDxCSXGKY-_wEB-Jjxmw62CMpYNk5xU_9qXbVRdLgidbANvJY7e6Ic5dzHNnx94DDjHhBG5JCaaCfw99bAebSxztG3QW7JDh7aleoPuv13dX38ntz28_rr7cEscbVYisGtCeCV5xqUVtmdCNFo1moZK-VU7S2movQQVgIOoQmqrmraDW2yBb7_kF-nScO6f4Z4FczNhnB8NgJ9guNRWVvGaUbfDDf_AhLmnadjMV25_Umm-IHZFLMecEwcypH21aDaNmD8YcgzHbf5s9GLNuPe9Pg5d2BP_ccUpiAx9PwGZnh5Ds5Pr87KTk1bYA_wd7BJhw</recordid><startdate>20050201</startdate><enddate>20050201</enddate><creator>HERRLINGER, Ulrich</creator><creator>RIEGER, Johannes</creator><creator>STEINBACH, Joachim P</creator><creator>NÄGELE, Thomas</creator><creator>DICHGANS, Johannes</creator><creator>WELLER, Michael</creator><general>Springer</general><general>Springer Nature B.V</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7TK</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope></search><sort><creationdate>20050201</creationdate><title>UKT-04 trial of continuous metronomic low-dose chemotherapy with methotrexate and cyclophosphamide for recurrent glioblastoma</title><author>HERRLINGER, Ulrich ; RIEGER, Johannes ; STEINBACH, Joachim P ; NÄGELE, Thomas ; DICHGANS, Johannes ; WELLER, Michael</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c387t-628e9d153236954a159895891f26db7c604a9d6e7fe1e54ff8243b50adaf6bdd3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2005</creationdate><topic>Adult</topic><topic>Angiogenesis Inhibitors - administration & dosage</topic><topic>Angiogenesis Inhibitors - therapeutic use</topic><topic>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</topic><topic>Biological and medical sciences</topic><topic>Brain Neoplasms - drug therapy</topic><topic>Brain Neoplasms - mortality</topic><topic>Brain Neoplasms - secondary</topic><topic>Breast Neoplasms - drug therapy</topic><topic>Breast Neoplasms - mortality</topic><topic>Breast Neoplasms - pathology</topic><topic>Cyclophosphamide - administration & dosage</topic><topic>Disease-Free Survival</topic><topic>Dose-Response Relationship, Drug</topic><topic>Drug Administration Schedule</topic><topic>Drug Resistance, Neoplasm</topic><topic>Female</topic><topic>Glioblastoma - drug therapy</topic><topic>Glioblastoma - mortality</topic><topic>Glioblastoma - secondary</topic><topic>Hormones. Endocrine system</topic><topic>Humans</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Methotrexate - administration & dosage</topic><topic>Middle Aged</topic><topic>Neoplasm Recurrence, Local - drug therapy</topic><topic>Neoplasm Recurrence, Local - mortality</topic><topic>Neurology</topic><topic>Pharmacology. Drug treatments</topic><topic>Tumors of the nervous system. Phacomatoses</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>HERRLINGER, Ulrich</creatorcontrib><creatorcontrib>RIEGER, Johannes</creatorcontrib><creatorcontrib>STEINBACH, Joachim P</creatorcontrib><creatorcontrib>NÄGELE, Thomas</creatorcontrib><creatorcontrib>DICHGANS, Johannes</creatorcontrib><creatorcontrib>WELLER, Michael</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Neurosciences Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><jtitle>Journal of neuro-oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>HERRLINGER, Ulrich</au><au>RIEGER, Johannes</au><au>STEINBACH, Joachim P</au><au>NÄGELE, Thomas</au><au>DICHGANS, Johannes</au><au>WELLER, Michael</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>UKT-04 trial of continuous metronomic low-dose chemotherapy with methotrexate and cyclophosphamide for recurrent glioblastoma</atitle><jtitle>Journal of neuro-oncology</jtitle><addtitle>J Neurooncol</addtitle><date>2005-02-01</date><risdate>2005</risdate><volume>71</volume><issue>3</issue><spage>295</spage><epage>299</epage><pages>295-299</pages><issn>0167-594X</issn><eissn>1573-7373</eissn><coden>JNODD2</coden><abstract>Glioblastoma is a highly angiogenic tumor with a dismal prognosis. Continuous oral low-dose chemotherapy with methotrexate (MTX) and cyclophosphamide (CPM) has modest activity in heavily pretreated patients with breast cancer. We explored the efficacy of 100 mg CPM daily and 5 mg MTX twice weekly in relapsed glioblastoma. Ten patients, 22-59 years old, with a Karnofsky score of 50% or higher who had failed at least two chemotherapies were accrued. No toxicity was observed. No patient showed a complete or partial response. Five of 10 patients progressed within 2 months of therapy. Another five patients progressed after 3-4.5 months. The median time to progression was 2.5 months. The median overall survival after start of MTX/CPM was 6.9 months (range 0.5-18.8 months). Since the progression-free survival rate at 6 months was 0%, the trial was prematurely closed.</abstract><cop>Dordrecht</cop><pub>Springer</pub><pmid>15735920</pmid><doi>10.1007/s11060-004-1726-y</doi><tpages>5</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0167-594X |
| ispartof | Journal of neuro-oncology, 2005-02, Vol.71 (3), p.295-299 |
| issn | 0167-594X 1573-7373 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_20634101 |
| source | MEDLINE; SpringerLink Journals - AutoHoldings |
| subjects | Adult Angiogenesis Inhibitors - administration & dosage Angiogenesis Inhibitors - therapeutic use Antineoplastic Combined Chemotherapy Protocols - therapeutic use Biological and medical sciences Brain Neoplasms - drug therapy Brain Neoplasms - mortality Brain Neoplasms - secondary Breast Neoplasms - drug therapy Breast Neoplasms - mortality Breast Neoplasms - pathology Cyclophosphamide - administration & dosage Disease-Free Survival Dose-Response Relationship, Drug Drug Administration Schedule Drug Resistance, Neoplasm Female Glioblastoma - drug therapy Glioblastoma - mortality Glioblastoma - secondary Hormones. Endocrine system Humans Male Medical sciences Methotrexate - administration & dosage Middle Aged Neoplasm Recurrence, Local - drug therapy Neoplasm Recurrence, Local - mortality Neurology Pharmacology. Drug treatments Tumors of the nervous system. Phacomatoses |
| title | UKT-04 trial of continuous metronomic low-dose chemotherapy with methotrexate and cyclophosphamide for recurrent glioblastoma |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-06T16%3A09%3A21IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=UKT-04%20trial%20of%20continuous%20metronomic%20low-dose%20chemotherapy%20with%20methotrexate%20and%20cyclophosphamide%20for%20recurrent%20glioblastoma&rft.jtitle=Journal%20of%20neuro-oncology&rft.au=HERRLINGER,%20Ulrich&rft.date=2005-02-01&rft.volume=71&rft.issue=3&rft.spage=295&rft.epage=299&rft.pages=295-299&rft.issn=0167-594X&rft.eissn=1573-7373&rft.coden=JNODD2&rft_id=info:doi/10.1007/s11060-004-1726-y&rft_dat=%3Cproquest_cross%3E20634101%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=219589993&rft_id=info:pmid/15735920&rfr_iscdi=true |